Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021
Rhea-AI Summary
Isoray (NYSE AMERICAN: ISR) plans to host a conference call on September 21, 2021, at 4:30 p.m. ET to discuss its financial results for Q4 and fiscal year ending June 30, 2021. A press release will be issued post-market regarding these results. The conference call can be accessed via phone or webcast, with the latter available until December 21, 2021. Isoray specializes in brachytherapy, providing targeted internal radiation treatments for cancers and is the sole producer of Cesium-131 brachytherapy seeds.
Positive
- None.
Negative
- None.
News Market Reaction – ISR
In the trading session that priced this news, ISR gained 0.47%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT
RICHLAND, Wash, Sept. 09, 2021 (GLOBE NEWSWIRE) -- – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended June 30, 2021 on Tuesday, September 21, 2021, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2021 after the close of the U.S. stock markets on September 21, 2021.
To listen to the conference call, please dial 844-369-8770. For callers outside the U.S., please dial 862-298-0840.
The conference call will be simultaneously webcast and can be accessed at https://www.webcaster4.com/Webcast/Page/2199/42729. The webcast will be available until December 21, 2021 following the conference call.
About Isoray
Isoray, Inc. is a medical technology company pioneering advanced treatment applications and devices to deliver targeted internal radiation treatments for cancers throughout the body. Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Follow us on LinkedIn and Twitter.
